Histone deacetylases (HDACs) regulate myriad cellular processes by catalyzing the hydrolysis of acetyl-L-lysine residues in histone and nonhistone proteins. The Zn 2+ -dependent class IIb enzyme HDAC6 regulates microtubule function by deacetylating α-tubulin, which suppresses microtubule dynamics and leads to cell cycle arrest and apoptosis. Accordingly, HDAC6 is a target for the development of selective inhibitors that might be useful in new therapeutic approaches for the treatment of cancer, neurodegenerative diseases, and other disorders. Here, we present high-resolution structures of catalytic domain 2 from Danio rerio HDAC6 (henceforth simply "HDAC6") complexed with compounds that selectively inhibit HDAC6 while maintaining nanomolar inhibitory potency: N-hydroxy-4-[(N(2-hydroxyethyl)-2-phenylacetamido)methyl)-benzamide)] (HPB), ACY-1215 (Ricolinostat), and ACY-1083. These structures reveal that an unusual monodentate Zn 2+ coordination mode is exploited by sterically bulky HDAC6-selective phenylhydroxamate inhibitors. We additionally report the ultrahigh-resolution structure of the HDAC6-trichostatin A complex, which reveals two Zn 2+ -binding conformers for the inhibitor: a major conformer (70%) with canonical bidentate hydroxamate-Zn 2+ coordination geometry and a minor conformer (30%) with monodentate hydroxamate-Zn 2+ coordination geometry, reflecting a free energy difference of only 0.5 kcal/mol. The minor conformer is not visible in lower resolution structure determinations. Structural comparisons of HDAC6-inhibitor complexes with class I HDACs suggest active site features that contribute to the isozyme selectivity observed in biochemical assays.
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protein crystallography | metalloenzyme | enzyme inhibitor | drug discovery | cancer chemotherapy R eversible lysine acetylation is a vital cellular strategy for the regulation of protein function (1) . Since the landmark discovery of histone acetylation more than 50 y ago by Allfrey et al. (2) , over 35,000 acetylation sites have been characterized in histone and nonhistone proteins involved in diverse biological processes such as the cell cycle, central carbon metabolism, and cellular signaling (3) (4) (5) (6) (7) . The acetylation of a protein L-lysine side chain is catalyzed by a histone acetyltransferase using acetyl CoA as a cosubstrate to yield acetyl-L-lysine (8, 9) , and this modification is reversed by a histone deacetylase (HDAC) to yield L-lysine and acetate (10) (11) (12) .
Aberrant up-regulation of HDAC activity is associated with tumorigenesis, developmental disorders, and neurodegenerative disease, so there is significant clinical interest in selectively blocking the activity of specific HDAC isozymes associated with a particular disease phenotype (13) (14) (15) (16) (17) . Human HDAC isozymes are classified into four groups based on phylogenetic analysis (18) : class I HDACs (1) (2) (3) 8) ; class IIa HDACs (4, 5, 7, 9) and class IIb HDACs (6, 10); class III HDACs, better known as sirtuins; and the sole class IV enzyme, HDAC11. Class I, II, and IV HDACs are Zn 2+ -or Fe
2+
-dependent enzymes (19) that adopt the arginase-deacetylase fold (11, (20) (21) (22) , while the sirtuins exhibit an unrelated fold and use cofactor NAD + (23). Among the HDAC isozymes, HDAC6 is distinct by virtue of its localization in the cytoplasm, as signaled by a serine/glutamate-rich repeat (24) , as well as its biological function (25, 26) . Additionally, HDAC6 is the only isozyme that contains two catalytic domains, CD1 and CD2, the structures of which have recently been solved (27, 28) . One of these domains, CD2, catalyzes the deacetylation of K40 of α-tubulin in the lumen of the microtubule (29, 30) . Consequently, inhibition of HDAC6 results in microtubule hyperacetylation and suppression of microtubule dynamics, leading to cell cycle arrest and apoptosis (30, 31) . HDAC6 is thus a critical target for the design of isozyme-selective inhibitors for use in cancer chemotherapy (32, 33) .
Four HDAC inhibitors are currently approved by the US Food and Drug Administration for cancer chemotherapy: the hydroxamic acids vorinostat, belinostat, and panobinostat and the cyclic depsipeptide romidepsin (34, 35) . These compounds generally inhibit all HDAC isozymes potently; that is, they are "pan-HDAC" inhibitors, so off-target effects are associated with their use due to inhibition of multiple metal-dependent HDACs (13) . However, significant advances have been made in the development of HDAC6-selective inhibitors, with examples being Tubastatin (36) (38) , ACY-1215 (Ricolinostat) (39) , and ACY-1083 (40) ( Table 1) . These inhibitors exhibit HDAC6 selectivities ranging from 12-fold to greater than 1,000-fold relative to class I Significance Histone deacetylase 6 (HDAC6) is a zinc metalloenzyme that serves as the tubulin deacetylase in the cell cytosol. Inhibition of tubulin deacetylase activity leads to suppression of microtubule dynamics, causing cell cycle arrest and apoptosis, which is a validated strategy for cancer chemotherapy. Selective inhibition of HDAC6 is clinically preferable, since unwanted inhibition of other HDAC isozymes can lead to undesirable offtarget effects. Here, X-ray crystal structures of HDAC6-inhibitor complexes reveal molecular features responsible for the isozyme selectivity measured in inhibition assays, including an unusual monodentate hydroxamate-Zn 2+ coordination mode as well as intermolecular interactions of bulky inhibitor substituents. These observations will inform the design of HDAC6-selective inhibitors with improved properties. To determine molecular features responsible for HDAC6-selective inhibition, we now report crystal structures of inhibitor complexes with the CD2 domain of Danio rerio (zebrafish) HDAC6, henceforth referred to simply as "HDAC6." Our recent structural and functional studies demonstrate that zebrafish HDAC6 is a validated and more readily crystallized surrogate of human HDAC6, the actual drug target (27) . Here, crystal structures of HDAC6 complexed with the HDAC6-selective inhibitors HPB and ACY-1083 reveal a monodentate hydroxamate-Zn 2+ -binding mode similar to that recently observed in the crystal structure of the HDAC6-HPOB complex (27) . Thus, this unusual binding mode is a signature of selectivity for the binding of phenylhydroxamate inhibitors with certain bulky substituents to HDAC6. In contrast, the crystal structure of the HDAC6 complex with Ricolinostat reveals a canonical bidentate hydroxamate-Zn 2+ chelate complex, so the isozyme selectivity of this inhibitor is rooted solely in the interactions of its bulky capping group. Intriguingly, the 1.05 Å-resolution structure of the HDAC6 complex with the R-stereoisomer of TSA reveals two Zn 2+ -binding modes for this pan-HDAC inhibitor: the major binding mode corresponds to the canonical bidentate hydroxamateZn 2+ complex observed in the previously determined 1.59 Å-resolution structure (27) , and the minor binding mode corresponds to the unusual monodentate Zn 2+ complex observed exclusively for HPB, HPOB, and ACY-1083. The phenyl linker group of HPB is sandwiched between F583 and F643 (Fig. 1B) . The peptoid capping group is observed in both the trans and cis conformations with respective occupancies of 0.66 and 0.34, corresponding to ΔG = 0.4 kcal/mol. This is within the range of 0.3-0.6 kcal/mol measured for peptoid trans-cis isomerization (41) , so the enzyme does not exhibit a clear preference for one conformation or the other. The phenyl group of the cis conformer makes a van der Waals contact with L1 loop residue P464; the energetically preferred trans conformation of the peptoid moiety allows the phenyl capping group to make a quadrupole-charge interaction with the side chain of R601 in an adjacent monomer. The hydroxyl moiety of the capping group forms a water-mediated hydrogen bond with S531 on the L2 loop (Fig. 1A) . The side chain of S531 accepts a hydrogen bond from the backbone NH group of the acetyl-Llysine substrate, an interaction that is unique to the HDAC6 active site (27 -O distance = 1.9 Å) and interacts with Y745 (O-O distance = 2.5 Å) ( Fig. 2A and Fig. S2 ). The hydroxamate C=O group accepts a hydrogen bond from the Zn 2+ -bound water molecule (O-O distance = 2.7 Å); this water molecule also hydrogen-bonds with H573 and H574. The hydroxamate NH group interacts with the side chain of Y745 (O-N distance = 2.7 Å).
The aromatic ring of the aminopyrimidine linker is sandwiched between F583 and F643 in a similar manner to that observed for the phenyl linker of HPB (Fig. 2B) . The hydroxyl side chain of S531 on the L2 loop accepts a hydrogen bond from the secondary amino group of the inhibitor (O-N distance = 3.1 Å) ( Fig. 2A) . The difluorocyclohexyl capping group adopts a chair conformation, and the equatorial fluorine atom packs against the edge of the F643 side chain (F-C distance = 3.6 Å). The phenyl capping group of the inhibitor makes van der Waals interactions with the side chains of P464 and F583. , and H574 accepts a hydrogen bond from the hydroxamate NH group (N-N distance = 2.9 Å). Hydrogen bond interactions with the tandem histidine residues suggest that H573 is in the positively charged imidazolium state and H574 is in the neutral imidazole state. These protonation states are consistent with the assignment of the second histidine in this tandem pair as a single general base-general acid in catalysis, as recently demonstrated for HDAC8 (42, 43) .
Two monomers reside in the asymmetric unit of this crystalline enzyme-inhibitor complex. In one monomer, the inhibitor capping group adopts two mutually exclusive conformations (Fig.  3) . In one conformation, the amide carbonyl of the inhibitor capping group forms a water-mediated hydrogen bond with S531 on the L1 loop. The aminopyrimidinyl ring nitrogen also forms a water-mediated hydrogen bond with D460. In the second conformation, a water-mediated hydrogen bond is formed between the amide carbonyl of the inhibitor capping group and H614 (one of the Zn 2+ ligands). The aminopyrimidinyl ring nitrogen also forms a water-mediated hydrogen bond with the carbonyl of P711.
HDAC6-TSA Complex. The 1.05 Å-resolution structure of HDAC6 complexed with the R-stereoisomer of TSA reveals significantly more detail in comparison to the previously reported 1.59 Å-resolution structure of this complex (PDB ID code 5EEK) (27) . Although the polypeptide backbones of HDAC6 in the ultrahigh-and high-resolution structures are essentially identical (rmsd = 0.064 Å for 315 Cα atoms), the ultrahigh-resolution structure reveals major and minor conformers for the hydroxamate group of TSA (Fig. 4A) . The minor conformation is not observable in crystal structures determined at lower resolution (27, 28) .
The major conformer of TSA (70% occupancy) corresponds to that described in the 1.59 Å-resolution structure, in which the canonical bidentate hydroxamate-Zn 2+ coordination mode is observed with O-Zn 2+ distances of 2.2 Å and 2.0 Å for the hydroxamate C=O and N-O − groups, respectively. Additionally, Y745 donates a hydrogen bond to the hydroxamate C=O, while H573 and H574 form hydrogen bonds with the N-O − group (Fig. 4B) .
The minor conformer of TSA (30% occupancy; Fig. 4C Interestingly, the secondary amino linker group of ACY-1083 donates a hydrogen bond directly to the hydroxyl group of S531 (Fig. 2) . S531 plays a key role in HDAC6-substrate recognition by accepting a hydrogen bond from the backbone NH group of the scissile acetyl-L-lysine substrate (27) . In class I enzymes such as HDAC8, D101 serves this role and accepts hydrogen bonds from both backbone NH groups flanking the scissile acetyl-L-lysine residue (44, 45) . While HPB lacks comparable functionality to make a direct interaction with S531, the hydroxyl group of its peptoid capping group forms a water-mediated hydrogen bond with S531 (Fig. 1) . Thus, direct or water-mediated hydrogen bonding with S531 is an interaction unique to the HDAC6 active site that confers some measure of isozyme selectivity.
The capping group of each inhibitor significantly contributes to HDAC6 affinity and selectivity. The capping group binds at the mouth of the active site cleft, and this region exhibits significant structural differences among the HDAC isozymes. In HDAC6, the L1 (H455-E465), L2 (M517-N536), and L7 (A706-Q716) loops can interact with inhibitor capping groups. The aromatic capping groups of HPB, ACY-1083, and HPOB pack primarily against the L1 loop; in addition, the capping group of Ricolinostat is sufficiently large to interact with the L7 loop as well.
The L1 loops of HDAC6 and class I HDACs adopt different conformations that significantly influence inhibitor binding (Fig. 6) . The phenyl group of the 260-fold selective inhibitor ACY-1083 packs tightly against the side chains of H463 and P464 in the L1 loop. Superposition of this complex with the structures of HDAC1, HDAC2, and HDAC3 shows that the L1 loops of class I HDACs adopt different conformations that constrict their active sites relative to HDAC6 (46) (47) (48) . This would create a steric clash with the binding conformation of ACY-1083. Thus, ACY-1083 binding to class I HDACs appears to be disfavored due to clashes between the large capping group and the L1 loop.
Ricolinostat has the largest capping group of the inhibitors shown in Table 1 , and this cap binds in a cleft between the L1 and L7 loops of HDAC6. Superposition with HDAC3 shows an ∼1 Å difference in these loop conformations, resulting in a narrowed cleft that would be less ideal for Ricolinostat binding. Table 1 and Fig. S4A ) was recently reported (28) . Curiously, despite its structural resemblance to HPOB and HPOB as a bulky phenylhydroxamate derivative, NextA is reported to bind with an alternative monodentate hydroxamate-Zn 2+ coordination geometry in which the hydroxamate carbonyl oxygen coordinates to Zn 2+ with a Zn
-O distance of 2.6 Å (Fig. S4B ). This separation is rather long for inner-sphere metal coordination. However, we inspected the electron density map generated with structure factor amplitudes and phases calculated from the final model of the enzyme-inhibitor complex deposited in the PDB (PDB ID code 5G0I); we suggest that the map better accommodates monodentate hydroxamateZn 2+ coordination by the hydroxamate N-O − group (Fig. S4C ). This binding mode refines with a Zn
-O distance of 2.2 Å, which is more typical for an inner-sphere metal coordination interaction. Additionally, the hydroxamate C=O group accepts a hydrogen bond from the Zn 2+ -bound water molecule, as observed for HPOB (27) , HPB ( Fig. 1) , ACY-1083 (Fig. 2) , as well as the minor conformer of TSA (Fig. 4) . Thus, we suggest that Fig. S4C illustrates the preferred binding mode of NextA.
Summary and Conclusions
Canonical bidentate hydroxamate-Zn 2+ coordination was first observed for inhibitor binding to thermolysin (50) , and exceptions are rarely observed (51 -binding mode can be exploited by bulky phenylhydroxamate inhibitors in the active site of HDAC6, even though the binding of these inhibitors would be disfavored in the more sterically constricted active sites of class I HDACs. Intriguingly, this alternative binding mode would disfavor the potential for the Zn 2+ -dependent Lossen rearrangement that could convert the hydroxamate moiety into a mutagenic isocyanate derivative (52) .
The linker groups of HDAC6-selective inhibitors can make direct or water-mediated hydrogen bonds with S531. This residue accepts a hydrogen bond from the backbone NH group of the acetyl-L-lysine substrate (27) , and this interaction is unique to the HDAC6 active site. Thus, an inhibitor that targets this interaction will exhibit selectivity for binding to HDAC6.
Finally, interactions of inhibitor capping groups at the mouth of the HDAC6 active site reveal that structural differences in the L1 loop also contribute to isozyme selectivity. Thus, specific interactions of the Zn 2+ -binding group, linker, and capping group together contribute to selectivity for HDAC6 binding.
Materials and Methods
HDAC6 CD2 from D. rerio (HDAC6) was recombinantly expressed using the MBP-tobacco etch virus-z6CD2-pET28a(+) vector and purified as previously described with minor modifications (27) , and crystalline enzyme-inhibitor complexes were prepared by cocrystallization in sitting drops. Crystals diffracted to 1.05-1.82 Å-resolution using synchrotron radiation, and each structure was solved by molecular replacement using the structure of unliganded HDAC6 (PDB 5EEM) (27) as a search probe for rotation and translation function calculations. Each structure was refined to convergence with R work values ranging from 0.113-0.184 and R free values ranging from 0.132-0.209. Full experimental details are outlined in Supporting Information, and data collection and refinement statistics are provided in Table S1 .
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